Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Inhibits TRKA, TRKB and TRKC, ROS1 and ALK kinase activity, suppressing oncogenic signalling in tumours driven by NTRK gene fusions or ROS1 rearrangements.
Indications / reported uses
Treatment of adults and paediatric patients with solid tumours harbouring an NTRK gene fusion, when disease is metastatic or surgery is likely to cause severe morbidity and there is no satisfactory alternative therapy or progression following treatment
Treatment of adults with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) under the applicable product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Entrectinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Entrectinib Permitted Daily Exposure (PDE) report (the Entrectinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Entrectinib Occupational Exposure Limit (OEL) report (the Entrectinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.